Common use of Royalty Rates Clause in Contracts

Royalty Rates. In further consideration of the licenses and other rights granted to NVS under this Agreement, during the Royalty Term for a Product in a country (other than for U.S. [***] Products), NVS will pay HMI royalties based on the aggregate Net Sales by NVS, its Affiliates, and its Sublicensees in a Calendar Year of (a) all Ophthalmic Products during the Royalty Term for each such Product in such country at the rates set forth in Table 11.7.1(a) below, (b) all [***] Products in the Ex-Vivo Field during the Royalty Term for each such Product in such country at the rates set forth in Table 11.7.1(b) below, and (c) all In-Vivo [***] Products outside of the U.S. during the Royalty Term for each such Product in such country at the rates set forth in Table 11.7.1(c) below. The royalty payments made pursuant to this Section 11.7.1 (Royalty Rates), the “Royalties” and the rates set forth in Table 11.7.1(a), Table 11.7.1(b), and Table 11.7.1(c), the “Royalty Rates.” (a) Royalty Rates for Ophthalmic Products (b) Royalty Rates for [***] Products in the Ex-Vivo Field Net Sales of all [***] Products in the Ex-Vivo Field Royalty Rate Royalty Floor [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% (c) Royalty Rates for In-Vivo [***] Products Net Sales of all In-Vivo [***] Products outside of the U.S. Royalty Rate Royalty Floor [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% By way of example only, if NVS receives $[***] in Net Sales of all Ophthalmic Products during a given Calendar Year, then the Royalties payable by NVS under this Section 11.7.1 (Royalty Rates) with respect to such Ophthalmic Products during such Calendar Year would be calculated as follows: Royalty = [***] = $[***] + [***] = $[***] + [***] = $[***] = $[***]

Royalty Rates. In further consideration of the licenses and other rights granted to NVS under this Agreement, during the Royalty Term for a Product in a country (other than for U.S. [***] Products), NVS a) Royalties Payable. Provention will pay HMI Jxxxxxx royalties based on the aggregate Net Sales by NVSProvention or its Related Parties (including sublicensees) of all Products in each Calendar Year at the royalty rates set out below. The period in which royalties are payable for Product sales in a given country ends upon the later to occur of (i) ten (10) years from the initial First Commercial Sale of a Product in the country or (ii) expiration of the last-to-expire Valid Claim within either the Jxxxxxx Patent Rights or Joint Patent Rights that is issued in such country of sale and, its Affiliatesbut for the licenses granted herein, and its Sublicensees would be infringed by such sale of such Product. Calendar Year Net Sales Royalty Rate (%) For aggregate Net Sales in a Calendar Year of (a) all Ophthalmic Products during the Royalty Term for each such Product in such country at the rates set forth in Table 11.7.1(a) below, (b) all less than or equal to [*****] Products in the Ex-Vivo Field during the Royalty Term for each such Product in such country at the rates set forth in Table 11.7.1(b) below, and U.S. Dollars (c) all In-Vivo US$[***] Products outside of the U.S. during the Royalty Term for each such Product in such country at the rates set forth in Table 11.7.1(c**]) below. The royalty payments made pursuant to this Section 11.7.1 (Royalty Rates), the “Royalties” and the rates set forth in Table 11.7.1(a), Table 11.7.1(b), and Table 11.7.1(c), the “Royalty Rates.” (a) Royalty Rates for Ophthalmic Products (b) Royalty Rates for [***] Products in the Ex-Vivo Field Net Sales of all [***] Products in the Ex-Vivo Field Royalty Rate Royalty Floor [***] [ ***]% [ For the portion of aggregate Net Sales in a Calendar Year of all Products greater than [*****] U.S. Dollars (US$[*****]) but less than or equal to [*****] U.S. Dollars (US$[*****]) [*****]% For the portion of aggregate Net Sales in a Calendar Year of all Products greater than [*****] [ U.S. Dollars (US$[*****]% [ ***]% ) [***] [ ***]% [ ***]% (c) Royalty Rates for In-Vivo [***] Products Net Sales of all In-Vivo [***] Products outside of the U.S. Royalty Rate Royalty Floor [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% By way of example onlyexample, if NVS receives aggregate Net Sales in a Calendar Year of all Products are $[***] in Net Sales of all Ophthalmic Products during a given Calendar Year**], then the Royalties payable by NVS royalties due under this Section 11.7.1 (Royalty Ratessection 8.2.1(a) with respect to such Ophthalmic Products during such Calendar Year would be calculated as follows: Royalty = [***] = $[***] + [***] = ], calculated as follows: $[***] + [***] = royalty on the first $[*****] = of Net Sales plus $[*****] royalty on the remaining $[*****] of Net Sales. By way of further example, if aggregate Net Sales in a Calendar Year of all Products are $[*****], the royalties due under this section 8.2.1(a) would be $[*****], calculated as follows: $[*****] royalty on the first $[*****] of Net Sales, plus $[*****] on the Net Sales greater than $[*****] but up to $[*****], plus $[*****] on the remaining $[*****] of Net Sales.

Royalty Rates. In further consideration Within thirty (30) days after the end of each Calendar Quarter (the licenses and other rights granted to NVS under this Agreement“Payment Period”), ASTELLAS shall pay THERAVANCE royalty [*]=CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. payments based on Net Sales in the Territory in such Payment Period during the Royalty Term for a Product in a country (other than for U.S. Term-Basic as follows: On total Calendar Year-to-date Net Sales up to and including [**] [*] Products), NVS will pay HMI royalties based on the aggregate On total Calendar Year-to-date Net Sales by NVS, its Affiliates, and its Sublicensees in a Calendar Year of (a) all Ophthalmic Products during the Royalty Term for each such Product in such country at the rates set forth in Table 11.7.1(a) below, (b) all greater than [**] and up to and including [*] Products [*] On total Calendar Year-to-date Net Sales greater than [*] [*] For example, where total Calendar Year-to-date Net Sales in all Countries in the Ex-Vivo Field during the Royalty Term for each such Product in such country at the rates set forth in Table 11.7.1(b) below, and (c) all In-Vivo Territory totals to [**] (for example, [*] Products outside in each of the U.S. during the Royalty Term for each such Product in such country at the rates set forth in Table 11.7.1(c) below. The royalty payments made pursuant to this Section 11.7.1 (Royalty Rates[*] Countries), the “Royalties” and the rates set forth in Table 11.7.1(a), Table 11.7.1(b), and Table 11.7.1(c), the “Royalty Rates.” (a) Royalty Rates for Ophthalmic Products (b) Royalty Rates for [***] Products in the Ex-Vivo Field Net Sales of all [***] Products in the Ex-Vivo Field Royalty Rate Royalty Floor [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% (c) Royalty Rates for In-Vivo [***] Products Net Sales of all In-Vivo [***] Products outside of the U.S. Royalty Rate Royalty Floor [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% By way of example only, if NVS receives $[***] in Net Sales of all Ophthalmic Products during a given Calendar Year, then the Royalties payable by NVS under this Section 11.7.1 (Royalty Rates) with respect to such Ophthalmic Products during such Calendar Year would be royalties are calculated as follows: Royalty = The first [**] is subject to the [*] = $rate, yielding [**] in royalties on that portion of the Calendar Year’s Net Sales. The next [*] + is subject to the [**] rate, yielding [*] = $in royalties on that portion of the Calendar Year’s Net Sales. The last [**] is subject to the [*] + rate, yielding [**] on that portion of the Calendar Year’s Net Sales. The total royalty for the year calculated under this Section 6.03(a) would be [*] = $plus [**] plus [*] = $for a grand total for the year of [*]. (To avoid doubt, depending upon the facts and circumstances, this total may be subject to adjustment under Sections 6.03(c)-(f).) The Parties agree that the [*] set forth in [*]] under this Agreement.

Royalty Rates. In further consideration of the licenses and other rights granted to NVS under this Agreement, during the Royalty Term for a Product in a country (other than for U.S. [***] SCD Products), NVS will pay HMI royalties based on the aggregate Net Sales by NVS, its Affiliates, and its Sublicensees in a Calendar Year of (a) all Ophthalmic Products during the Royalty Term for each such Product in such country at the rates set forth in Table 11.7.1(a) below, (b) all [***] Sickle Cell Products in the Ex-Vivo Field during the Royalty Term for each such Product in such country at the rates set forth in Table 11.7.1(b) below, and (c) all In-Vivo [***] SCD Products outside of the U.S. during the Royalty Term for each such Product in such country at the rates set forth in Table 11.7.1(c) below. The royalty payments made pursuant to this Section 11.7.1 (Royalty Rates), the “Royalties” and the rates set forth in Table 11.7.1(a), Table 11.7.1(b), and Table 11.7.1(c), the “Royalty Rates.” (a) Royalty Rates for Ophthalmic Products (b) Royalty Rates for [***] Sickle Cell Products in the Ex-Vivo Field Net Sales of all [***] Sickle Cell Products in the Ex-Vivo Field Royalty Rate Royalty Floor [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% (c) Royalty Rates for In-Vivo [***] SCD Products Net Sales of all In-Vivo [***] SCD Products outside of the U.S. Royalty Rate Royalty Floor [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% By way of example only, if NVS receives $[***] in Net Sales of all Ophthalmic Products during a given Calendar Year, then the Royalties payable by NVS under this Section 11.7.1 (Royalty Rates) with respect to such Ophthalmic Products during such Calendar Year would be calculated as follows: Royalty = [***] = $[***] + [***] = $[***] + [***] = $[***] = $[***]

Royalty Rates. In Subject to the terms and conditions of this Agreement (including Section 6.8), in further consideration of the licenses and other rights granted to NVS Amgen under this Agreement, during the Royalty Term for a Product in a country (other than for U.S. [***] Products)Amgen shall pay to Xencor royalties on worldwide, NVS will pay HMI royalties based on the aggregate Annual Net Sales of each Product by NVSAmgen, its AffiliatesAffiliates and Sublicensees: (i) Subject to Section 6.7(c) below, and its Sublicensees in a Calendar Year of (a) all Ophthalmic Products during the Royalty Term for each such Product in such country at the rates set forth out in Table 11.7.1(aA below if the Co-Funding Arrangement pursuant to Section 6.3 is in effect; and (ii) below, (b) all [***] Products in the Ex-Vivo Field during the Royalty Term for each such Product in such country at the rates set forth out in Table 11.7.1(b) belowB below if the Co-Funding Arrangement has been terminated. Notwithstanding the foregoing, and (c) all Inin the event the Co-Vivo [***] Products outside Funding Arrangement is in effect during the performance of a portion of the U.S. during the Royalty Term for each such Product in such country Post-Exercise Development Plan but is subsequently terminated, Amgen shall pay to Xencor royalties on Net Sales of Products (x) at the rates set forth out in Table 11.7.1(c) below. The royalty payments made A below (as adjusted pursuant to Section 6.7(c)) until such time as the difference between the cumulative royalties paid under this Section 11.7.1 6.7 for all Products and the cumulative royalties for Net Sales of such Products that would have been payable under Table B below equals the aggregate amount paid by Xencor to Amgen for Development Costs pursuant to the Co-Funding Arrangement under Section 6.3, and (Royalty Rates), the “Royalties” and y) at the rates set forth out in Table 11.7.1(aB following the period described in (x), Table 11.7.1(b), and Table 11.7.1(c), the “. TABLE A — CO-FUNDING ROYALTY RATES Annual Net Sales of Product Royalty Rates.” (a) Royalty Rates for Ophthalmic Products (b) Royalty Rates for Rate […***…] Products in the Ex-Vivo Field […***…] % *** Confidential Treatment Requested 30 […***…] […***…] % […***…] […***…] % […***…] […***…] % TABLE B — BASE ROYALTY RATES Annual Net Sales of all Product Royalty Rate […***…] Products in the Ex-Vivo Field Royalty Rate Royalty Floor […***…] [ % […***]% [ …] […***]…] % […***…] [ […***]…] % [ […***]% …] […***…] [ ***]% [ ***]% (c) Royalty Rates for In-Vivo [***] Products Net Sales of all In-Vivo [***] Products outside of the U.S. Royalty Rate Royalty Floor [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% By way of example only, if NVS receives $[***] in Net Sales of all Ophthalmic Products during a given Calendar Year, then the Royalties payable by NVS under this Section 11.7.1 (Royalty Rates) with respect to such Ophthalmic Products during such Calendar Year would be calculated as follows: Royalty = [***] = $[***] + [***] = $[***] + [***] = $[***] = $[***]

Royalty Rates. In further consideration Subject to the other terms of the licenses and other rights granted to NVS under this AgreementSection 11.7, during the Royalty Term for a Product in a country (other than for U.S. [***] Products)Term, NVS will pay HMI royalties based Astellas shall make quarterly non-refundable, non-creditable royalty payments to Cytokinetics on the aggregate Net Sales by NVS, its Affiliates, and its Sublicensees in a Calendar Year of (a) all Ophthalmic Products during the Royalty Term for each such Collaboration Product in such country at the applicable royalty rate set forth below. Net Sales shall be aggregated on a Compound-by-Compound basis across all Indications. (i) Other Skeletal Sarcomere Activator Approved for [ * ] Indication(s) and/or [ * ] Indications Only. The royalty rates set forth in Table 11.7.1(a) belowthe table below shall apply to each Collaboration Product containing an Other Skeletal Sarcomere Activator, (b) all [***] Products in unless and until any of the Ex-Vivo Field during the Royalty Term for each such Product in such country at the royalty rates set forth in Table 11.7.1(bSections 11.7(a)(ii), (iii) below, and (civ) all In-Vivo [***] Products outside below become applicable to such Collaboration Product. Once any of the U.S. during the Royalty Term for each such Product in such country at the royalty rates set forth in Table 11.7.1(c) below. The royalty payments made pursuant to this Section 11.7.1 (Royalty RatesSections 11.7(a)(ii), (iii) and (iv) below become applicable to such Collaboration Product, the “Royalties” and the royalty rates set forth in Table 11.7.1(athis Section 11.7(a)(i) shall no longer apply. [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] (ii) Other Skeletal Sarcomere Activator Approved for [ * ] Indication(s) [ * ] Indications). The royalty rates set forth in the table below shall apply to Collaboration Product containing an Other Skeletal Sarcomere Activator after the first Marketing Approval of such Collaboration Product in [ * ] Indication for which Cytokinetics exercises the Cytokinetics Co-Funding Option [ * ] for such Collaboration Product and [ * ] such Collaboration Product for [ * ] Indication. [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] (iii) Other Skeletal Sarcomere Activator Approved for [ * ] Indication(s) and [ * ] Indication(s)/ [ * ] Indication(s). The royalty rates set forth in the table below shall apply to Collaboration Product containing an Other Skeletal Sarcomere Activator after the first Marketing Approval of such Collaboration Product for[ * ] Indication (except during the Cytokinetics Commercialization Period) and provided that such Collaboration Product has obtained Marketing Approval for a [ * ] Indication or [ * ] Indication, provided that: (A) where such Collaboration Product is approved for [ * ] Indication, if Cytokinetics either did not exercise the Cytokinetics Co-Funding Option [ * ] for such Collaboration Product, then Astellas shall have the right to [ * ] as set forth in Section [ * ]; (B) if [ * ] for such Collaboration Product for such approved [ * ] Indication(s), Table 11.7.1(bthen Cytokinetics shall have the right to [ * ] as set forth in Section [ * ]; and (C) if both the [ * ] apply, then Section [ * ] shall apply. [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] (iv) Other Skeletal Sarcomere Activator Approved for [ * ]. The royalty rates set forth in the table below shall apply to Collaboration Product containing an Other Skeletal Sarcomere Activator after the first Marketing Approval of such Collaboration Product for one or more [ * ] Indication(s) [ * ] such Collaboration Product obtains Marketing Approval in any [ * ] Indication or [ * ] Indication (except during the Cytokinetics Commercialization Period), provided that [ * ] for such Collaboration Product for any of such approved [ * ] Indication(s), then [ * ] shall have the right to [ * ] as set forth in Section [ * ]. [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] (v) [ * ]. (1) [ * ]. Under circumstances where [ * ] has the right to [ * ] as set forth in this Section 11.7, and subject to Section 11.7(a)(v)(3) below, the [ * ] set forth in this Section 11.7 or Section 11.8(b) shall [ * ] shall no longer apply. (2) [ * ]. Under circumstances where [ * ] has the right to [ * ] as set forth in this Section 11.7 or Section 11.8(b), and Table 11.7.1(csubject to Section 11.7(a)(v)(3) below, the [ * ] shall be [ * ]shall no longer apply. (3) If, for a particular Collaboration Product, [ * ] under Section 11.7(a)(iii), then each Party shall [ * ] of the applicable [ * ]shall have the right to [ * ] under Section 11.7(a)(iii) but only [ * ] shall have the right to [ * ] but only [ * ]. [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. (4) “[ * ]” means, with respect to a Collaboration Product [ * ] Indication(s) for which [ * ] for such [ * ] Indication. If [ * ] for such Collaboration Product and [ * ] for such Collaboration Product, then the [ * ] for such Collaboration Product [ * ] was deemed to have [ * ] for such Collaboration Product pursuant to Section [ * ] such Collaboration Product and [ * ] will be included in [ * ]. (5) “[ * ]” means, with respect to a Collaboration Product which [ * ] one or more [ * ] Indication(s), the “Royalty Rates[ * ] Indication(s)). If [ * ] Indication [ * ]such Collaboration Product [ * ].” (a) Royalty Rates for Ophthalmic Products (b) Royalty Rates for [***] Products in the Ex-Vivo Field Net Sales of all [***] Products in the Ex-Vivo Field Royalty Rate Royalty Floor [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% (c) Royalty Rates for In-Vivo [***] Products Net Sales of all In-Vivo [***] Products outside of the U.S. Royalty Rate Royalty Floor [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% By way of example only, if NVS receives $[***] in Net Sales of all Ophthalmic Products during a given Calendar Year, then the Royalties payable by NVS under this Section 11.7.1 (Royalty Rates) with respect to such Ophthalmic Products during such Calendar Year would be calculated as follows: Royalty = [***] = $[***] + [***] = $[***] + [***] = $[***] = $[***]

Royalty Rates. In further consideration Subject to the other terms of the licenses and other rights granted to NVS under this AgreementSection 11.7, during the Royalty Term for Term, Astellas shall make quarterly non-refundable, non-creditable royalty payments to Cytokinetics on the Net Sales of each Collaboration Product at the applicable royalty rate set forth below. Net Sales shall be aggregated on a Product in a country Compound-by-Compound basis across all Indications. (other than for U.S. i) [***] Products), NVS will pay HMI royalties based on the aggregate Net Sales by NVS, its Affiliates, and its Sublicensees in a Calendar Year of (a) all Ophthalmic Products during the Royalty Term for each such Product in such country at the Activators. The royalty rates set forth in Table 11.7.1(a) below, (b) all the table below shall apply to Collaboration Product containing [**] Activator. [*] Products in the Ex-Vivo Field during the Royalty Term [*] [*] [*] [*] [*] [*] [*] (ii) [*] Activator Approved for each such Product in such country at the [*] Indication(s) and/or [*]. The royalty rates set forth in Table 11.7.1(b) below, and (c) all In-Vivo the table below shall apply to each Collaboration Product containing a [***] Products outside Activator, unless and until any of the U.S. during the Royalty Term for each such Product in such country at the royalty rates set forth in Table 11.7.1(c) below. The royalty payments made pursuant to this Section 11.7.1 (Royalty RatesSections 11.7(a)(iii), (iv) and (v) below become applicable to such Collaboration Product. Once any of the “Royalties” and the royalty rates set forth in Table 11.7.1(aSections 11.7(a)(iii), Table 11.7.1(b(iv) and (v) below become applicable to such Collaboration Product, the royalty rates set forth in this Section 11.7(a)(ii) shall no longer apply. [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] (iii) [*] Activator Approved for [*] Indication(s) ([*] Indications). The royalty rates set forth in the table below shall apply to Collaboration Product containing a [*] Activator after the first Marketing Approval of such Collaboration Product in [*] Indication for which Cytokinetics exercises the Cytokinetics Co-Funding Option [*] for such Collaboration Product and [*] such Collaboration Product for [*] Indication. [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] (iv) [*] Activator Approved for [*] Indication(s) and [*] Indication(s)/[*] Indication(s). The royalty rates set forth in the table below shall apply to Collaboration Product containing a [*] Activator after the first Marketing Approval of such Collaboration Product for [*] Indication (except during the Cytokinetics Commercialization Period) and provided that such Collaboration Product has obtained Marketing Approval for a [*] Indication or [*] Indication, provided that: (A) where such Collaboration Product is approved for [*] Indication, if Cytokinetics either did not exercise the Cytokinetics Co-Funding Option or [*] for such Collaboration Product, then Astellas shall have the right to [*] as set forth in Section [*]; (B) if [*] for such Collaboration Product for such approved [*] Indication(s), then Cytokinetics shall have the right to [*] as set forth in Section [*]; and (C) if both the [*] apply, then Section [*] shall apply. [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] (v) [*] Activator Approved for [*]. The royalty rates set forth in the table below shall apply to Collaboration Product containing a [*] Activator after the first Marketing Approval of such Collaboration Product for one or more [*] Indication(s) [*] such Collaboration Product obtains Marketing Approval in any [*] Indication or [*] Indication (except during the Cytokinetics Commercialization Period), provided that [*] for such Collaboration Product for any of [*] Indication(s), then [*] shall have the right to [*] as set forth in Section [*]. [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] (vi) [*]. (1) [*] Under circumstances where [*] has the right to [*] as set forth in this Section 11.7, and subject to Section 11.7(a)(vi)(3) below, the [*] set forth in this Section 11.7 or Section 11.8(b) shall [*] shall no longer apply. (2) [*] Under circumstances where [*] has the right to [*] as set forth in this Section 11.7 or Section 11.8(b), and Table 11.7.1(csubject to Section 11.7(a)(vi)(3) below, the [*] shall be [*] shall no longer apply. (3) If, for a particular Collaboration Product, [*] under Section 11.7(a)(iv), then each Party shall [*] of the applicable [*] shall have the right to [*] under Section 11.7(a)(iv) but only [*] shall have the right to [*] but only [*]. (4) [*] means, with respect to a Collaboration Product [*] Indication(s) for which [*] for such [*] Indication. If [*] [*] such Collaboration Product and [*] such Collaboration Product, then the [*] such Collaboration Product [*] was deemed to have [*] such Collaboration Product pursuant to Section [*] such Collaboration Product and [*] will be included in the [*]. (5) [*] means, with respect to a Collaboration Product which [*] one or more [*] Indication(s), the “Royalty Rates.” (a) Royalty Rates for Ophthalmic Products (b) Royalty Rates for [**] Indication(s). If [*] Products in the Ex-Vivo Field Net Sales of all Indication [**] Indication(s) and [*] Products in the Ex-Vivo Field Royalty Rate Royalty Floor Indication [***] [ **such Collaboration Product [*]% [ ***]% [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% (c) Royalty Rates for In-Vivo [***] Products Net Sales of all In-Vivo [***] Products outside of the U.S. Royalty Rate Royalty Floor [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% [***] [ ***]% [ ***]% By way of example only, if NVS receives $[***] in Net Sales of all Ophthalmic Products during a given Calendar Year, then the Royalties payable by NVS under this Section 11.7.1 (Royalty Rates) with respect to such Ophthalmic Products during such Calendar Year would be calculated as follows: Royalty = [***] = $[***] + [***] = $[***] + [***] = $[***] = $[***]